| Literature DB >> 23616792 |
Paweł Borowiecki1, Małgorzata Milner-Krawczyk, Jan Plenkiewicz.
Abstract
Racemic 1-(β-hydroxypropyl)azoles were prepared by solvent-free direct regioselective ring opening of 1,2-propylene oxide with imidazole or 1,2,4-triazole. Lipase-catalyzed transesterification of alcohols with vinyl acetate resulted in kinetic enantiomers resolution. Separated (S)-enantiomers of (+)-1-(1H-imidazol-1-yl)propan-2-ol and (+)-1-(1H-1,2,4-triazol-1-yl)propan-2-ol were quaternized with alkyl bromides or iodides, yielding novel optically active ionic liquids. Racemic salts were tested against a wide range of microorganisms.Entities:
Keywords: antibiotics; antifungal agents; double derivatization; enzyme catalysis; ionic liquids
Year: 2013 PMID: 23616792 PMCID: PMC3628848 DOI: 10.3762/bjoc.9.56
Source DB: PubMed Journal: Beilstein J Org Chem ISSN: 1860-5397 Impact factor: 2.883
Scheme 1Synthesis of optically active ILs. Reagents and conditions: (i) 1,2-propylene oxide (1.1 equiv), 32 °C, 24 h; (ii) vinyl acetate (5 equiv), Novozyme SP 435, 2-methyl-2-butanol, rt, 48 h, magnetic stirrer; (iii) vinyl acetate (5 equiv), enzyme, 2-methyl-2-butanol/MTBE (methyl tert-butyl ether), rt, 250 rpm; (iv) RX (3 equiv), Δ, dry CH3CN.
Lipase-catalyzed resolution of racemic 1-(1H-imidazol-1-yl)propan-2-ol (±)-3a.
| Entry | Enzyme | Solvent | Conv.a (%) | Product | eeb (%) | Yieldd (%) | ||
| 1 | Amano PS | MTBEe | 20 | 30 | alcohol | 41 | 98 | 95 |
| 2 | 2-methyl-2-butanole | 26 | 32 | alcohol | 46 | 103 | 43 | |
| 3 | Amano AK | MTBEe | 5 | 47 | alcohol | 88 | 584 | 97 |
| 4 | 2-methyl-2-butanole | 22 | 41 | alcohol | 70 | 419 | 95 | |
| 5 | 2-methyl-2-butanolf | 43 | 45 | alcohol | 80 | 492 | 94 | |
| 6 | Novozym SP 435 | MTBEe | 1.5 | 57 | alcohol | 97 | 26 | 95 |
| 7 | MTBEf | 7 | 59 | alcohol | 98 | 23 | 53 | |
| 8 | 2-methyl-2-butanole | 7 | 30 | alcohol | 40 | 41 | 99 | |
| 9 | 2-methyl-2-butanolf | 11 | 53 | alcohol | 82 | 16 | 70 | |
| 10 | 2-methyl-2-butanolf | 12 | 57 | alcohol | 92 | 17 | 40 | |
| 11 | Amano PS-IM | MTBEf | 3 | 39 | alcohol | 64 | 386 | 98 |
| 12 | MTBEf | 4 | 46 | alcohol | 82 | 254 | 66 | |
| 13 | 2-methyl-2-butanolf | 5 | 38 | alcohol | 60 | 368 | 86 | |
aConversion was calculated from the enantiomeric excess of the starting material (ees) and the product (eep) according to the formula: conv. = ees/(ees + eep). bDetermined by HPLC analysis by using a Chiralcel OD-H column. cCalculated according to Chen et al. [56], by using the equation: E = ln[(1 − conv.)(1 − ees)]/ln[(1 − conv.)(1 + ees)]. dIsolated yield after column chromatography. eConditions: (±)-3a 300 mg, lipase 100 mg, solvent 3 ml, vinyl acetate 1 g (5 equiv), 250 rpm at rt. fConditions: (±)-3a 300 mg, lipase 50 mg, solvent 3 ml, vinyl acetate 1 g (5 equiv), 250 rpm at rt.
Lipase-catalyzed resolution of racemic 1-(1H-1,2,4-triazol-1-yl)propan-2-ol (±)-3b.
| Entry | Enzyme | Solvent | Conv.a (%) | Product | eeb (%) | Yieldd (%) | ||
| 1 | Amano PS | MTBEe | 65 | 40 | alcohol | 57 | 20 | 77 |
| 2 | 2-methyl-2-butanole | 132 | 39 | alcohol | 56 | 27 | 85 | |
| 3 | Amano AK | MTBEe | 12 | 41 | alcohol | 63 | 33 | 97 |
| 4 | 2-methyl-2-butanole | 30 | 37 | alcohol | 54 | 33 | 93 | |
| 5 | 2-methyl-2-butanole | 49 | 54 | alcohol | 98 | 56 | 93 | |
| 6 | Novozym SP 435 | MTBEe | 7 | 45 | alcohol | 49 | 6 | 82 |
| 7 | 2-methyl-2-butanole | 8 | 40 | alcohol | 40 | 6 | 95 | |
| 8 | Amano PS-IM | MTBEf | 5 | 47 | alcohol | 74 | 25 | 76 |
| 9 | 2-methyl-2-butanolf | 10 | 41 | alcohol | 62 | 36 | 98 | |
aConversion was calculated from the enantiomeric excess of the starting material (ees) and the product (eep) according to the formula conv. = ees/(ees + eep). bDetermined by HPLC analysis by using Chiralcel OD-H column. cCalculated according to Chen et al. [56], by using the equation: E = ln[(1 − conv.)(1 − ees)]/ln[(1 - conv.)(1 + ees)]. dIsolated yield after column chromatography. eConditions: (±)-3a 300 mg, lipase 100 mg, solvent 3 ml, vinyl acetate 1 g (5 equiv), 250 rpm at rt. fConditions: (±)-3a 300 mg, lipase 50 mg, solvent 3 ml, vinyl acetate 1 g (5 equiv), 250 rpm at rt.
Scheme 2Conversion of (+)-5a and (+)-5b into MPA esters 9a, 9b and 10a, 10b.
Figure 1Model for the configurational correlation of MPA esters 9a, 9b and 10a, 10b.
Figure 2The 1H NMR spectra of the derivatives of two unreacted chiral alcohols (+)-5a (top) and (+)-5b (bottom). Symbols marked in green represent protons shielded by the phenyl ring of chiral auxiliary (MPA); blue labels stand for unaffected protons.
Synthesis of chiral imidazolium (+)-7a–h and triazolium ILs (+)-8a–f.
| Entry | IL | R | X | Yield (%) | [α]Da | ||
| 1 | (+)- | C3H7 | Br | 96 | 65 | 92 | +23.6 |
| 2 | (+)- | C3H5 | Br | 96 | 65 | 93 | +25.3 |
| 3 | (+)- | C4H9 | Br | 96 | 80 | 94 | +17.2 |
| 4 | (+)- | C5H11 | Br | 96 | 82 | 82 | +15.4 |
| 5 | (+)- | C7H15 | I | 96 | 82 | 92 | +16.3 |
| 6 | (+)- | C10H21 | I | 96 | 82 | 92 | +15.8 |
| 7 | (+)- | C12H25 | I | 96 | 120 | 86 | +14.2 |
| 8 | (+)- | C16H33 | I | 96 | 120 | 81 | +11.4 |
| 9 | (+)- | C3H7 | Br | 48 | 65 | 98 | +18.8 |
| 10 | (+)- | C3H5 | Br | 48 | 65 | 94 | +15.6 |
| 11 | (+)- | C4H9 | Br | 48 | 80 | 90 | +17.7 |
| 12 | (+)- | C5H11 | Br | 48 | 82 | 78 | +15.4 |
| 13 | (+)- | C7H15 | I | 48 | 82 | 87 | +10.2 |
| 14 | (+)- | C10H21 | I | 48 | 82 | 92 | +8.5 |
aSpecific rotation; c solution in chloroform (c 1.0).
Growth inhibition halo (cm) for the racemic imidazolium and triazolium CILs (25 mM).
| CIL | R | ||||||
| (±)- | C3H7 | – | – | – | – | – | – |
| (±)- | C5H11 | – | – | – | – | – | – |
| (±)- | C7H15 | 1.20 ± 0.00 | 1.03 ± 0.04 | 1.05 ± 0.00 | 1.20 ± 0.00 | 1.73 ± 0.04 | – |
| (±)- | C10H21 | 1.40 ± 0.00 | 1.23 ± 0.04 | 1.10 ± 0.00 | 2.30 ± 0.00 | 2.80 ± 0.00 | + |
| (±)- | C3H7 | – | – | – | – | – | – |
| (±)- | C5H11 | – | – | – | – | – | – |
| (±)- | C7H15 | – | – | – | – | 1.00 ± 0.00 | – |
| (±)- | C10H21 | 1.30 ± 0.14 | 1.25 ± 0.07 | 1.08 ± 0.04 | 1.90 ± 0.14 | 1.25 ± 0.07 | 1.18 ± 0.04 |
–: No inhibition; +: total growth inhibition
The MIC (mM) values for the racemic imidazolium and triazolium CILs.
| CIL | R | ||||||
| (±)- | C10H21 | 0.5 | 0.4 | >9.5 | 0.5 | 0.2 | 0.3 |
| (±)- | C12H25 | 0.3 | 0.5 | 1.6 | 0.5 | 0.3 | 0.1 |
| (±)- | C16H33 | 0.2 | 0.5 | 9.0 | 0.2 | 0.3 | 0.3 |
| (±)- | C10H21 | 1.7 | 4.8 | 5.5 | 3.0 | 0.5 | 0.9 |
Antifungal activity (% of control) of the racemic imidazolium and triazolium CILs (1mM).
| CIL | R | |||||||
| (±)- | C3H7 | 89.97 ± 0.00 | 99.60 ± 0.88 | 98.38 ± 0.81 | 100.78 ± 0.78 | 98.70 ± 1.67 | 98.81 ± 3.76 | 93.00 ± 7.87 |
| (±)- | C5H11 | 90.12 ± 5.10 | 96.56 ± 3.82 | 101.32 ± 1.02 | 92.89 ± 1.18 | 96.71 ± 1.58 | 99.49 ± 5.01 | 104.17 ± 7.04 |
| (±)- | C7H15 | 110.20 ± 4.01 | 87.55 ± 8.03 | 82.73 ± 0.66 | 89.92 ± 5.47 | 96.55 ± 1.24 | 90.65 ± 2.14 | 59.29 ± 3.20 |
| (±)- | C10H21 | 59.70 ± 5.12 | 63.00 ± 1.45 | 68.40 ± 1.00 | 91.55 ± 0.68 | 99.54 ± 1.76 | 113.32 ± 3.17 | 99.43 ± 4.21 |
| (±)- | C12H25 | 47.58 ± 7.08 | 61.33 ± 1.50 | 66.78 ± 3.68 | 87.20 ± 0.72 | 93.73 ± 1.97 | 88.21 ± 6.76 | 85.02 ± 5.16 |
| (±)- | C16H33 | 74.35 ± 11.65 | 94.53 ± 3.72 | 74.13 ± 8.51 | 93.66 ± 2.96 | 103.10 ± 45.34 | 92.77 ± 2.65 | 91.87 ± 2.28 |
| (±)- | C3H7 | 95.16 ± 3.07 | 102.28 ± 0.76 | 99.19 ± 2.04 | 98.40 ± 3.45 | 101.30 ± 1.67 | 101.58 ± 2.37 | 91.20 ± 6.68 |
| (±)- | C5H11 | 94.65 ± 3.43 | 93.89 ± 5.06 | 105.29 ± 2.64 | 93.31 ± 1.60 | 97.53 ± 6.64 | 112.05 ± 0.00 | 93.05 ± 24.81 |
| (±)- | C7H15 | 105.10 ± 2.32 | 98.39 ± 5.47 | 95.58 ± 2.78 | 104.12 ± 1.58 | 99.82 ± 3.43 | 104.63 ± 7.64 | 92.64 ± 4.45 |
| (±)- | C10H21 | 77.35 ± 5.95 | 73.58 ± 5.28 | 92.64 ± 7.14 | 98.65 ± 3.12 | 104.59 ± 2.59 | 93.47 ± 2.87 | 95.58 ± 4.82 |